That offer would be too low.
Just look at the label...
PROVENGE is an autologous cellular
immunotherapy indicated for the treatment of
asymptomatic or minimally symptomatic metastatic
castrate resistant (hormone refractory) prostate
The U.S. demand for this therapy will far exceed demand for years. The label is much broader than I expected.
Good luck to all my fellow PC patients. We have real HOPE now.
Whop ever is buying the shares is not selling guys!!! wake up.....the stock was too low even at 7 Billion market cap. In 5 years sales will be 3 billion 2 X Sales!!!! shoot if you pay 10 Billion, you get your money back in 5 years.............
I doubt you have any basis/proof re $100 offer.
HOWEVER, your sentiment makes sense.
Approval has been granted, so uncertainty's been removed. Likely many companies expressed interest in ROW partnering, so had inside look at the company <=> performed quasi-due-dilegence. Share price rocketed from $39 to $50 close yesterday to $56 mid-session today; unlikely it will retreat meaningfully, so every day an Acquirer waits is a day the dndn market cap rises. Financially, it makes absolute sense to strike before price rises further. The longer a buyer waits, the more time for others to develop interest & competing bid.